Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many mechanistic/indication statements are generally consistent with the label, and several interaction/safety concepts are directionally supported; however, multiple claims are not supported or are contradicted by the provided labeling excerpt (notably FDA approval year and several adverse-effect frequency assertions). Several warnings/monitoring and “good option/not best” statements are not substantiated by label language.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication that belongs to the HMG-CoA reductase inhibitor class.
Label indicates LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase (12.1).
Lipitor works by blocking the production of cholesterol in the liver.
Mechanism: selective inhibitor of HMG-CoA reductase (12.1).
Lipitor reduces low-density lipoprotein (LDL) cholesterol in the blood.
Label: LIPITOR lowers plasma cholesterol and lipoprotein levels and reduces LDL-C (12.1; 14.2; 1.2).
Lipitor has been widely prescribed to treat high cholesterol.
Label supports treatment of hyperlipidemia (1.2), but does not quantify “widely prescribed.”
Lipitor has been widely prescribed to reduce the risk of cardiovascular disease.
Label indicates cardiovascular risk reduction indications (1.1), but does not quantify “widely prescribed.”
Lipitor remains effective for cholesterol management.
Label indicates therapeutic response is seen and maintained during chronic therapy (14.2).
Lipitor can interact with other medications, such as warfarin.
Provided label sections do not mention warfarin specifically; therefore only general 'interactions' are supported, but this specific example is not.
Lipitor can interact with other medications, such as cyclosporine.
Label: risk of myopathy increased with cyclosporine (5.1; 7; 7.3).
Interactions with other medications may affect Lipitor efficacy or increase the risk of side effects.
Label describes increased risk of myopathy/rhabdomyolysis with interacting drugs (5.1; 7). Efficacy effects are not directly stated in provided excerpts.
Patients with liver disease or impaired liver function may need to avoid Lipitor.
Contraindication: active liver disease including unexplained persistent elevations in hepatic transaminase levels (4.1); caution/monitoring language in 5.2.
Unsupported Statements
Lipitor was approved by the FDA in 1997.
FDA approval year is not provided in the supplied labeling excerpt.
Generic versions of Lipitor became available after patent expiration in 2011.
Patent/ANDA/generic availability timeline is not provided in the supplied labeling excerpt.
A study published in JAMA found Lipitor was associated with a higher risk of muscle damage compared to other statins.
No JAMA study or comparative risk statement is present in the supplied labeling excerpt.
A study published in JAMA found Lipitor was associated with a higher risk of kidney problems compared to other statins.
No JAMA study or comparative kidney-risk statement is present in the supplied labeling excerpt.
Lipitor is still a good option for some patients.
This patient-selection/value judgment is not stated in the supplied label excerpt.
Lipitor is not the best option for everyone.
This comparative “best option” language is not present in the supplied label excerpt.
Choosing a medication like Lipitor should consider the individual patient's needs and medical history.
While label includes individualization of dose (2.1), it does not support this general counseling statement as written.
A study published in the Journal of Managed Care & Specialty Pharmacy found that generic Lipitor was more cost-effective than other statins, including rosuvastatin and ezetimibe.
No cost-effectiveness study or comparison is present in the supplied labeling excerpt.
Patients with a history of muscle damage or kidney problems may need to avoid Lipitor or switch to a different medication.
Label excerpt addresses myopathy/rhabdomyolysis and monitoring/withholding/discontinuation in acute serious myopathy conditions (5.1), but does not state a blanket “avoid or switch” based on a history of muscle damage or kidney problems.
Patients with liver disease or impaired liver function may need to have their liver function monitored closely when taking Lipitor.
Label recommends liver function tests prior to and at 12 weeks following initiation and any elevation of dose, and periodically thereafter; it does not explicitly tie this to 'liver disease or impaired liver function' as phrased.
Lipitor can interact with other medications, such as warfarin.
Warfarin is not mentioned in the provided label sections.
Common side effects of Lipitor include muscle damage.
Label lists adverse reactions leading to discontinuation (e.g., myalgia) and other commonly reported adverse reactions; it does not label “muscle damage” as a common side effect.
Common side effects of Lipitor include liver problems.
Label mentions alanine aminotransferase increase and hepatic enzyme increase leading to discontinuation, but does not support 'liver problems' as a 'common side effect' in the broad way claimed.
Common side effects of Lipitor include kidney problems.
Label excerpt does not list kidney problems as common adverse reactions; it mentions acute renal failure secondary to rhabdomyolysis as a rare-case scenario (5.1).
Patients with liver disease or impaired liver function may need to avoid Lipitor or have their liver function monitored closely.
Avoidance is supported only for active liver disease/contraindication (4.1), but the combined phrasing about 'impaired liver function' and 'monitored closely' is not directly supported as written (5.2 addresses testing schedule in general).
Contradictions
Important Omissions
Clear contraindications and usage limitations for pregnancy and nursing (e.g., contraindicated in women who are pregnant or may become pregnant; women requiring treatment should not breastfeed).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or overstated adverse-effect frequency (e.g., 'common side effects' as muscle/liver/kidney problems) and unsupported comparative risk/avoidance/switch guidance could mislead assessment of risk; omission of pregnancy/nursing contraindication reduces safety completeness.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided FDA labeling excerpt (FDA approval year, generic availability timeline, JAMA/other study findings, warfarin interaction example) and several safety statements overstate what is 'common' (muscle/liver/kidney problems).
Suggested Improvement
Remove or qualify unsupported claims not present in the label; align adverse-reaction statements to those actually listed (e.g., myalgia, liver enzyme increases) and avoid asserting 'common' muscle/kidney problems. Add on-label contraindication counseling for pregnancy and nursing when making safety-related statements.